A retrospective analysis comparing FOLFIRI with aflibercept or bevacizumab efficacy and toxicity in the 2nd line chemotherapy (CT) in patients (pts) with metastatic colorectal cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
Indications Colorectal cancer
Focus Therapeutic Use

24 Jul 2020 Primary endpoint (Progression-free survival (PFS) and objective response rate (ORR)) has not been met according to the results presented at the 22nd World Congress on Gastrointestinal Cancer
24 Jul 2020 New trial record
04 Jul 2020 Results presented at the 22nd World Congress on Gastrointestinal Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com